Findings from CONFIRM - a large real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) versus insulin glargine U300 - will be presented on Monday, 25 June 2018 at the American Diabetes Association's 78th Scientific Sessions (ADA) in Orlando, US. The retrospective, non-interventional comparative effectiveness study, which included more than 4,000 adults with type 2 diabetes who were starting basal insulin for the first time, showed that after six months those treated with Tresiba® had significantly lower HbA1c compared to those treated with insulin glargine U300 (-1.5% vs. -1.2% respectively; p=0.029).[1]
As a secondary endpoint, there was a 30% lower rate of hypoglycaemic episodes with Tresiba® compared to insulin glargine U300 (p=0.045).[1] In this study, hypoglycaemic events, ranging from mild to severe, were registered using the International Classification of Diseases (ICD) codes 9/10 following diagnosis from a physician.[2]
This real-world study also showed in another secondary endpoint that people treated with Tresiba® were more likely to stay on their treatment. Those treated with insulin glargine U300 had a 37% higher rate of discontinuing treatment after two years (p<0 .001="" sup="">[1]0>
No comments:
Post a Comment